<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">World J Surg Oncol</journal-id>
      <journal-title-group>
        <journal-title>World Journal of Surgical Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25314924</article-id>
      <article-id pub-id-type="pmc">4210534</article-id>
      <article-id pub-id-type="publisher-id">1788</article-id>
      <article-id pub-id-type="doi">10.1186/1477-7819-12-314</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Large cell neuroendocrine carcinoma of the ovary: a case report and a brief review of the literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ki</surname>
            <given-names>Eun Young</given-names>
          </name>
          <address>
            <email>mdkey@catholic.ac.kr</email>
          </address>
          <xref ref-type="aff" rid="Aff9"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Park</surname>
            <given-names>Jong Sup</given-names>
          </name>
          <address>
            <email>jspark@catholic.ac.kr</email>
          </address>
          <xref ref-type="aff" rid="Aff9"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Keun Ho</given-names>
          </name>
          <address>
            <email>hohoho@catholic.ac.kr</email>
          </address>
          <xref ref-type="aff" rid="Aff9"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bae</surname>
            <given-names>Seog Nyeon</given-names>
          </name>
          <address>
            <email>seognbae@catholic.ac.kr</email>
          </address>
          <xref ref-type="aff" rid="Aff9"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Hur</surname>
            <given-names>Soo Young</given-names>
          </name>
          <address>
            <email>hursy@catholic.ac.kr</email>
          </address>
          <xref ref-type="aff" rid="Aff9"/>
        </contrib>
        <aff id="Aff9">Department of Obstetrics and Gynecology, Seoul St. Mary&#x2019;s Hospital, The Catholic University of Korea, Banpodaero, Seocho-Gu, Seoul, Korea </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>15</day>
        <month>10</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>15</day>
        <month>10</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>12</volume>
      <elocation-id>314</elocation-id>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>3</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>3</day>
          <month>10</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Ki et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Large cell neuroendocrine carcinoma (LCNC) of the ovary, or ovarian undifferentiated non-small cell carcinoma of neuroendocrine type, is a rare entity that is frequently associated with ovarian surface epithelial tumors. Few cases have been reported in the literature. LCNC is an aggressive tumor with tendency to present at advanced stages and to cause death after a short postoperative duration. We report three cases of LCNC diagnosed histopathologically. Immunohistochemically, the tumor cells were positive for chromogranin A, NSE, CD56, and pancytokeratin. The patients were treated postoperatively with combination chemotherapy. Due to the rarity of LCNC, the general consensus on standard therapy is not established. Although most patients are at stage I, the biological aggressiveness and poor prognosis of the tumors have been reported in previous reports despite extensive surgery and chemotherapy.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Ovary</kwd>
        <kwd>Neuroendocrine carcinoma</kwd>
        <kwd>Non-small cell</kwd>
        <kwd>Large cell</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Ovarian neoplasms associated with hormone production and secretion include sex-cord-stromal and germ cell tumors [<xref ref-type="bibr" rid="CR1">1</xref>]. Another tumor showing endocrine features is small cell carcinoma, which is divided into hypercalcemic and pulmonary types [<xref ref-type="bibr" rid="CR2">2</xref>]. According to the World Health Organization (WHO), undifferentiated non-small cell carcinoma of neuroendocrine type is synonymous with large cell neuroendocrine carcinoma (LCNC) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. LCNC is a rare cancer, and 27 cases have been reported in the literature so far [<xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR7">7</xref>]. The clinical behaviors of LCNC are aggressive and show poor prognosis despite being diagnosed in the early stages [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Most of the reported LCNCs are associated with teratoma or epithelial tumor, such as serous and mucinous tumors [<xref ref-type="bibr" rid="CR10">10</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>].</p>
      <p>We report three cases of large cell neuroendocrine carcinoma of the ovary with a literature review.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <sec id="Sec3">
        <title>Case 1</title>
        <p>A 77-year old woman visited our clinic with a 1-month history of abdominal distension and discomfort. She had been diagnosed with coronary artery disease prior to this presentation. Physical examination showed ascites and firm/fixed mass in the suprapubic area. In the left supraclavicular area, nodular masses were palpable, raising suspicion of metastatic lymph nodes. Computed tomography (CT) revealed a huge heterogenous soft tissue mass in the pelvic cavity. Chest CT showed an extensive, conglomerated soft tissue density in the left supraclavicular area. The CA125 value was 124 u/ml. She underwent an exploratory laparotomy. At operation, a 15-cm ovarian mass was found to adhere to the uterus, bladder, rectum, and small intestine. About 500&#xA0;ml of ascites was noted. The uterus, pelvic mass, and neck masses were removed, and there were large amounts of intraoperative bleeding. The pathologic diagnosis of the ovarian mass was undifferentiated non-small cell neuroendocrine carcinoma of the ovary. Immunohistochemical staining was negative for synaptophysin, but positive for chromogranin A and NSE (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The pathologic examination revealed that the neck mass had malignant cells with massive necrosis. The cytologic evaluation of the ascites showed malignant cells. She received 1 session of etoposide 100&#xA0;mg/m<sup>2</sup> for 2&#xA0;days along with 1 session of carboplatin 300&#xA0;mg/m<sup>2</sup> at 14&#xA0;days after operation. She died of septic shock after 45 postoperative days.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Microscopic pictures. (a)</bold> Neuroendocrine carcinoma: low-power field shows solid sheets (H&amp;E, &#xD7;40). <bold>(b)</bold> Cells with larger vesicular nuclei: prominent nucleoli, and mitotic activity (H&amp;E, &#xD7;400). <bold>(c)</bold> Chromogranin A is expressed in a neuroendocrine carcinoma (&#xD7;400). <bold>(d)</bold> Pancytokeratin is expressed in a neuroendocrine carcinoma (&#xD7;400). <bold>(e)</bold> NSE is expressed focally in a neuroendocrine carcinoma (&#xD7;400). <bold>(f)</bold> CD56 is expressed in a neuroendocrine carcinoma (&#xD7;400).</p></caption><graphic xlink:href="12957_2014_1788_Fig1_HTML" id="d30e344"/></fig></p>
      </sec>
      <sec id="Sec4">
        <title>Case 2</title>
        <p>A 58-year old woman was referred to our clinic after being diagnosed with neuroendocrine carcinoma of the ovary at a private clinic. She had complained of abdominal discomfort for 1&#xA0;month prior to this presentation and was found to have an ovarian mass. She had no remarkable past medical history or family history. She underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy, total omentectomy, and pelvic lymph node sampling at the private clinic. The pathologic diagnosis of the mass was undifferentiated non-small cell neuroendocrine carcinoma restricted to the left ovary. The surgical stage was Ia. She was treated with 6 sessions of a combination chemotherapy consisting of paclitaxel 175&#xA0;mg/m<sup>2</sup> and cisplatin 90&#xA0;mg/m<sup>2</sup>. Five months after the last chemotherapy, a recurrent mass was noted around the para-aortic lymph node area by CT scan. It measured about 2.3&#x2009;&#xD7;&#x2009;1.6&#xA0;cm on the left para-aortic area. The CA125 level was 1.6 u/ml. She underwent secondary debulking operation. At the laparotomy, a 3-cm mass was noted in the left para-aortic lymph node. The mass was removed and histopathologically examined. The pathologic diagnosis of the mass was large cell neuroendocrine carcinoma recurrent in the para-aortic lymph node. She was treated with 7 sessions of taxotere 75&#xA0;mg/m<sup>2</sup> every 3&#xA0;weeks. She died of multiple organ failure at 17&#xA0;months after initial diagnosis.</p>
      </sec>
      <sec id="Sec5">
        <title>Case 3</title>
        <p>A 67-year old woman was referred to our clinic because of an ovarian mass. She had visited a private clinic due to urinary frequency, and the ovarian mass was found by transvaginal sonography. At presentation, CT scan revealed a 13-cm multiseptated mixed solid and cystic mass in the left ovary which was suspected of cystadenocarcinoma. The CA125 level was 71.8 u/ml. She underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic lymph node dissection, para-aortic lymph node dissection, and total omentectomy along with multiple biopsy. At operation, the mass was composed of solid and cystic portions (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). The pathologic diagnosis of the mass was neuroendocrine carcinoma of non-small cell type arising from the left ovary which involved the pelvic peritoneum. Immunohistochemical staining was positive for pancytokeratin, CD56, and pancytokeratin, and was focally positive for NSE; however, it was negative for synaptophysin and chromogranin A (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The surgical stage was IIb. She was treated with a combination chemotherapy consisting of paclitaxel 175&#xA0;mg/m<sup>2</sup> and carboplatin 4-hour area-under-the curve (AUC4) every 3&#xA0;weeks. She is still healthy 5&#xA0;months after operation.<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>A photograph of an ovarian mass.</bold> It is composed of solid and cystic lesions.</p></caption><graphic xlink:href="12957_2014_1788_Fig2_HTML" id="d30e384"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec6" sec-type="discussion">
      <title>Discussion</title>
      <p>Neuroendocrine carcinoma originates from endocrine cells of the diffuse neuroendocrine system, which in turn consists of a variety of cells present in the central and peripheral nervous systems as well as several endocrine organs. These cells can produce biologically active amines and peptides which can act as neurotransmitters, hormones, or paracrine regulators. Neuroendocrine cells are present in normal epithelium of the female genital tract [<xref ref-type="bibr" rid="CR10">10</xref>]. It has been shown that primitive endodermal cells have the potential to differentiate into both endocrine and other cell types and that ovarian neuroendocrine tumors may develop from non-neuroendocrine cells through activation of genes that promote neuroendocrine differentiation [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
      <p>In general, the incidence of epithelial ovarian cancer increases in older patients (age &gt;50&#xA0;years), but the LCNC can be developed in premenopausal and postmenopausal women, ranging from 22 to 76&#xA0;years. Similarly, in our report the age of patients ranged from 58 to 77&#xA0;years, and mean age was 67.3&#xA0;years. Clinical symptoms at initial presentation are variable. The most common clinical manifestation was abdominal pain in 7 cases [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], followed by abdominal distension (n = 4) [<xref ref-type="bibr" rid="CR14">14</xref>&#x2013;<xref ref-type="bibr" rid="CR17">17</xref>], and an abdominal palpable mass (n = 3) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], abdominal bloating (n = 3) [<xref ref-type="bibr" rid="CR3">3</xref>], abdominal discomfort (n = 1) [<xref ref-type="bibr" rid="CR2">2</xref>], postmenopausal vaginal bleeding (n = 1) [<xref ref-type="bibr" rid="CR3">3</xref>], and dysarthria due to brain metastasis (n = 1) [<xref ref-type="bibr" rid="CR8">8</xref>]. In our report, abdominal distension, abdominal discomfort, and urinary frequency occurred in one case each. The urinary frequency may have been due to compression of the bladder by the huge ovarian mass. Most of the LCNCs are partially solid or partially cystic, with size ranging from 9 and 30&#xA0;cm (mean size, 16.6&#xA0;cm) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. In this report, the mean size of the mass was 13&#xA0;cm, and the mass was also partially solid or cystic.</p>
      <p>The histogenesis of neuroendocrine tumors is unknown. The following hypotheses have been proposed. First, neuroendocrine cells have been presented in the normal epithelium of benign, borderline, and malignant tumors of the female genital tract. These cells serve as an origin of neuroendocrine tumors of the ovary. Second, primitive endocrine cells can differentiate into endocrine and other cell types. Third, ovarian neuroendocrine tumors may develop from non-neuroendocrine cells, which activate genes promoting neuroendocrine differentiation [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p>
      <p>CA125 is a tumor antigen found in 75 to 83% of all epithelial ovarian cancers [<xref ref-type="bibr" rid="CR19">19</xref>]. Serum CA125 levels correlate with cancer stages or responses to treatment. A rise in CA125 levels usually precedes tumor progression or recurrence. Therefore, CA125 can be used to monitor epithelial ovarian cancer. In LCNC, serum CA125 levels are not specific to clinical courses. Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> shows reported serum CA125 levels in previous studies. The CA125 levels range from 5.7 to 917 u/ml. Some authors have reported other tumor markers. Ngan <italic>et al.</italic>
[<xref ref-type="bibr" rid="CR9">9</xref>] have reported that 5-hydroxyindole acetic acid (5-HIAA) markedly increase in neuroendocrine carcinomas of the ovary. They also stated that 5-HIAA is a sensitive tumor marker of neuroendocrine components.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Clinicopathologic review, adjuvant treatment, CA125 levels, and follow-up periods of reported cases</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Author</th><th>Mean age (years)</th><th>Chief complaint</th><th>Adjuvant treatment</th><th>CA125 (u/ml)</th><th>Follow-up periods (months)</th></tr></thead><tbody><tr><td>Lindboe <italic>et al</italic>. [<xref ref-type="bibr" rid="CR2">2</xref>]</td><td>64</td><td>Abdominal discomfort, nausea</td><td>Cisplatin&#x2009;+&#x2009;Bleomycin&#x2009;+&#x2009;Etoposide</td><td>380</td><td>9</td></tr><tr><td>Shakuntala <italic>et al</italic>. [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td>40</td><td>Abdominal distension</td><td>Cisplatin&#x2009;+&#x2009;Etoposide</td><td>280</td><td>6</td></tr><tr><td>Hinde <italic>et al.</italic>
[<xref ref-type="bibr" rid="CR15">15</xref>]</td><td>54</td><td>Abdominal distension</td><td>Carboplatin&#x2009;+&#x2009;Paclitaxcel</td><td>_</td><td>8</td></tr><tr><td rowspan="2">Dundr <italic>et al</italic>. [<xref ref-type="bibr" rid="CR8">8</xref>]</td><td rowspan="2">73</td><td rowspan="2">Dysarthria, difficulty in verbal expression because of brain metastasis</td><td>Carboplatin&#x2009;+&#x2009;Paclitaxcel</td><td>94</td><td>12</td></tr><tr><td>Cyberknife on brain lesion</td><td/><td/></tr><tr><td>Tsuji <italic>et al</italic>. [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td>46</td><td>Abdominal distension</td><td>Carboplatin&#x2009;+&#x2009;Paclitaxcel</td><td>914</td><td>Died after 4&#xA0;months postoperatively</td></tr><tr><td>Aslam <italic>et al</italic>. [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td>76</td><td>Abdominal pain</td><td>None</td><td>Within the normal range</td><td>Died postoperatively</td></tr><tr><td rowspan="2">Chenevert <italic>et al</italic>. [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td>53</td><td>Abdominal mass</td><td>Carboplatin&#x2009;+&#x2009;Paclitaxcel</td><td>80</td><td>Died after 3&#xA0;months postoperatively</td></tr><tr><td>53</td><td>Abdominal distension</td><td>Cisplatin&#x2009;+&#x2009;Etoposide</td><td>5.7</td><td>Died after 7&#xA0;months postoperatively</td></tr><tr><td>Behnam <italic>et al</italic>. [<xref ref-type="bibr" rid="CR5">5</xref>]</td><td>27</td><td>Pelvic mass</td><td>Carboplatin&#x2009;+&#x2009;Paclitaxcel</td><td/><td>10</td></tr><tr><td rowspan="5">Veras <italic>et al.</italic>
[<xref ref-type="bibr" rid="CR3">3</xref>] 11 cases</td><td rowspan="5">22 to 63 [46.7]</td><td rowspan="2">6: abdominal pain</td><td rowspan="2"/><td rowspan="2"/><td>Mean survival: 12</td></tr><tr><td>Mean follow-up periods: 28</td></tr><tr><td>3: abdominal bloating</td><td/><td/><td/></tr><tr><td>1: pelvic mass</td><td/><td/><td/></tr><tr><td>1: postmenopausal bleeding</td><td/><td/><td/></tr><tr><td rowspan="2">Ki <italic>et al.</italic>
</td><td>77</td><td/><td/><td/><td/></tr><tr><td/><td>Abdominal distension</td><td>Carboplatin&#x2009;+&#x2009;Etoposide</td><td>124</td><td>Died after 1.5&#xA0;months postoperatively</td></tr><tr><td/><td>58</td><td>Abdominal discomfort</td><td>Cisplatin&#x2009;+&#x2009;Paclitaxcel</td><td>none</td><td>Died after 17&#xA0;months postoperatively</td></tr><tr><td/><td/><td/><td>Single Docetaxel</td><td/><td/></tr><tr><td/><td>67</td><td>Urinary frequency</td><td>Carboplatin&#x2009;+&#x2009;Paclitaxcel</td><td>71.8</td><td>5</td></tr></tbody></table></table-wrap></p>
      <p>CT and magnetic resonance imaging (MRI) usually show non-specific findings in LCNC cases. Radiologic studies are not useful for the differential diagnosis of LCNC from other ovarian tumors [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p>
      <p>The differential diagnosis of LCNC includes other primary or secondary neuroendocrine tumors. Small cell carcinoma has smaller cells with molding and necrosis. Metastatic neuroendocrine cancer cells are usually not found in the epithelial layer of the ovary. Several non-neuroendocrine tumors, such as teratoma, sex-cord stromal tumor, and Sertoli-Leydig cell tumor, may show neuroendocrine differentiation. These biphasic tumors can usually be distinguished from LCNC by identifying non-neuroendocrine components [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Immunohistochemistry is important to diagnose neuroendocrine carcinoma. The most commonly used non-hormonal immunohistochemical markers are chromogranin A, synaptophysin, cytokeratin, and CD56. NSE and Leu-7 lack specificity and may not be conclusive for neuroendocrine differentiation when other stains are negative [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Our specimens were immunohistochemically positive for chromogranin A, NSE, CD56, and pancytokeratin.</p>
      <p>There is no standard treatment of LCNC. Various combination chemotherapy regimens, such as platinum, paclitaxcel, etoposide, and bleomycin have been used in previous studies. The survival periods varied among the groups. A combination of platinum and paclitaxcel has most frequently been used with shorter survival.</p>
    </sec>
    <sec id="Sec7" sec-type="conclusions">
      <title>Conclusion</title>
      <p>LCNC is rare, shows aggressive behaviors and poor responses to treatment. Due to the rarity of LCNCs, general consensus on the standard therapy has not yet been established. Although patients with LCNC are at stage I, their survival rates are relatively low due to biological aggressiveness despite extensive surgery and chemotherapy. We reported three cases of advanced or early LCNC with a brief review of the literature.</p>
    </sec>
    <sec id="Sec8">
      <title>Consent</title>
      <p>Written informed consent was obtained. The study was approved by the Institutional Review Board of our hospital (KC14ZISE0113).</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-list>
          <def-item>
            <term>5-HIAA</term>
            <def>
              <p>5-hydroxyindole acetic acid</p>
            </def>
          </def-item>
          <def-item>
            <term>AUC4</term>
            <def>
              <p>4-hour area-under-the curve</p>
            </def>
          </def-item>
          <def-item>
            <term>CT</term>
            <def>
              <p>computed tomography</p>
            </def>
          </def-item>
          <def-item>
            <term>H&amp;E</term>
            <def>
              <p>hematoxylin and eosin</p>
            </def>
          </def-item>
          <def-item>
            <term>LCNC</term>
            <def>
              <p>large cell neuroendocrine carcinoma</p>
            </def>
          </def-item>
          <def-item>
            <term>MRI</term>
            <def>
              <p>magnetic resonance image</p>
            </def>
          </def-item>
          <def-item>
            <term>WHO</term>
            <def>
              <p>World Health Organization.</p>
            </def>
          </def-item>
        </def-list>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>EYK wrote the initial draft. SYH and JSP performed the surgery and helped collect clinical information. SYH, KHL and SNB designed the study and made the manuscript of this paper. All authors have read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eichhorn</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Scully</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Primary ovarian small cell carcinoma of pulmonary type. A clinicopathologic, immunohistologic, and flow cytometric analysis of 11 cases</article-title>
          <source>Am J Surg Pathol</source>
          <year>1992</year>
          <volume>16</volume>
          <fpage>926</fpage>
          <lpage>938</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-199210000-00002</pub-id>
          <pub-id pub-id-type="pmid">1384368</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lindboe</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Large cell neuroendocrine carcinoma of the ovary: case report and review of the literature</article-title>
          <source>APMIS</source>
          <year>2007</year>
          <volume>115</volume>
          <fpage>169</fpage>
          <lpage>176</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0463.2007.apm_570.x</pub-id>
          <pub-id pub-id-type="pmid">17295684</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Veras</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Deavers</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Malpica</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathological and immunohistochemical study of 11 cases</article-title>
          <source>Am J Surg Pathol</source>
          <year>2007</year>
          <volume>31</volume>
          <fpage>774</fpage>
          <lpage>782</lpage>
          <pub-id pub-id-type="doi">10.1097/01.pas.0000213422.53750.d1</pub-id>
          <pub-id pub-id-type="pmid">17460463</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khurana</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Tornos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>EG</given-names>
            </name>
          </person-group>
          <article-title>Ovarian neuroendocrine carcinoma associated with a mucinous neoplasm</article-title>
          <source>Arch Pathol Lab Med</source>
          <year>1994</year>
          <volume>118</volume>
          <issue>10</issue>
          <fpage>1032</fpage>
          <lpage>1034</lpage>
          <pub-id pub-id-type="pmid">7944890</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Behnam</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Primary ovarian undifferentiated non-small cell carcinoma, neuroendocrine type</article-title>
          <source>Gynecol Oncol</source>
          <year>2004</year>
          <volume>92</volume>
          <issue>1</issue>
          <fpage>372</fpage>
          <lpage>375</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ygyno.2003.09.031</pub-id>
          <pub-id pub-id-type="pmid">14751189</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hirasawa</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Ovarian neuroendocrine carcinoma associated with mucinous carcinoma and teratoma</article-title>
          <source>Nihon Rinsho</source>
          <year>2004</year>
          <volume>62</volume>
          <issue>5</issue>
          <fpage>973</fpage>
          <lpage>978</lpage>
          <pub-id pub-id-type="pmid">15148829</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eichhorn</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Scully</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Ovarian neuroendocrine carcinomas of non-small-cell type associated with surface epithelial adenocarcinomas. A study of five cases and review of the literature</article-title>
          <source>Int J Gynecol Pathol</source>
          <year>1996</year>
          <volume>15</volume>
          <issue>4</issue>
          <fpage>303</fpage>
          <lpage>314</lpage>
          <pub-id pub-id-type="doi">10.1097/00004347-199610000-00002</pub-id>
          <pub-id pub-id-type="pmid">8886877</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dundr</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fischerov&#xE1;</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pov&#xFD;sil</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cibula</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Primary pure large-cell neuroendocrine carcinoma of the ovary</article-title>
          <source>Pathol Res Pract</source>
          <year>2008</year>
          <volume>204</volume>
          <issue>2</issue>
          <fpage>133</fpage>
          <lpage>137</lpage>
          <pub-id pub-id-type="doi">10.1016/j.prp.2007.09.004</pub-id>
          <pub-id pub-id-type="pmid">18164557</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ngan</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>HK</given-names>
            </name>
          </person-group>
          <article-title>The value of tumor markers in a mixed tumor, mucinous and neuroendocrine carcinoma of the ovary</article-title>
          <source>Gynecol Oncol</source>
          <year>1989</year>
          <volume>35</volume>
          <fpage>272</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="doi">10.1016/0090-8258(89)90059-0</pub-id>
          <pub-id pub-id-type="pmid">2478429</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eichhorn</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Neuroendocrine tumors of the genital tract</article-title>
          <source>Am J Clin Pathol</source>
          <year>2001</year>
          <volume>115</volume>
          <issue>1</issue>
          <fpage>S94</fpage>
          <lpage>S112</lpage>
          <pub-id pub-id-type="pmid">11993694</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>KTK</given-names>
            </name>
          </person-group>
          <article-title>Composite large-cell neuroendocrine carcinoma and surface epithelial-stromal neoplasm of the ovary</article-title>
          <source>Int J Surg Pathol</source>
          <year>2000</year>
          <volume>8</volume>
          <issue>2</issue>
          <fpage>169</fpage>
          <lpage>174</lpage>
          <pub-id pub-id-type="doi">10.1177/106689690000800214</pub-id>
          <pub-id pub-id-type="pmid">11493984</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Collins</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Cheung</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ngan</surname>
              <given-names>HYS</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>SYW</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>MK</given-names>
            </name>
          </person-group>
          <article-title>Primary mixed neuroendocrine and mucinous carcinoma of the ovary</article-title>
          <source>Arch Gynecol Obstet</source>
          <year>1991</year>
          <volume>248</volume>
          <fpage>139</fpage>
          <lpage>143</lpage>
          <pub-id pub-id-type="doi">10.1007/BF02390091</pub-id>
          <pub-id pub-id-type="pmid">1850226</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aslam</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Khulpateea</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Neuroendocrine tumour of the ovary</article-title>
          <source>J Obstet Gynaecol</source>
          <year>2009</year>
          <volume>29</volume>
          <issue>5</issue>
          <fpage>448</fpage>
          <lpage>449</lpage>
          <pub-id pub-id-type="doi">10.1080/01443610902946903</pub-id>
          <pub-id pub-id-type="pmid">19603336</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shakuntala</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Devi</surname>
              <given-names>KU</given-names>
            </name>
            <name>
              <surname>Shobha</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bafna</surname>
              <given-names>UD</given-names>
            </name>
            <name>
              <surname>Geetashree</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Pure large cell neuroendocrine carcinoma of ovary: a rare clinical entity and review of literature</article-title>
          <source>Case Rep Oncol Med</source>
          <year>2012</year>
          <volume>2012</volume>
          <fpage>120727</fpage>
          <lpage>120731</lpage>
          <pub-id pub-id-type="pmid">23304586</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fatemi Hinde</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Rare tumors of ovary: case report and literature review</article-title>
          <source>Open J Pathol</source>
          <year>2012</year>
          <volume>02</volume>
          <issue>03</issue>
          <fpage>81</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.4236/ojpathology.2012.23015</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chenevert</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bassette</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Plante</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tetu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dube</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Mixed ovarian large cell neuroendocrine carcinoma, mucinous adenocarcinoma, and teratoma: a report of two cases and review of the literature</article-title>
          <source>Pathol Res Pract</source>
          <year>2009</year>
          <volume>205</volume>
          <issue>9</issue>
          <fpage>657</fpage>
          <lpage>661</lpage>
          <pub-id pub-id-type="doi">10.1016/j.prp.2009.01.013</pub-id>
          <pub-id pub-id-type="pmid">19577382</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsuji</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Togami</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shintomo</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Fukamachi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Douchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Taguchi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Ovarian large cell neuroendocrine carcinoma</article-title>
          <source>J Obstet Gynaecol Res</source>
          <year>2008</year>
          <volume>34</volume>
          <issue>4 Pt 2</issue>
          <fpage>726</fpage>
          <lpage>730</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1447-0756.2008.00916.x</pub-id>
          <pub-id pub-id-type="pmid">18840191</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choi</surname>
              <given-names>YD</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Nam</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Ovarian neuroendocrine carcinoma, non-small cell type, associated with serous carcinoma</article-title>
          <source>Gynecol Oncol</source>
          <year>2007</year>
          <volume>104</volume>
          <issue>3</issue>
          <fpage>747</fpage>
          <lpage>752</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ygyno.2006.11.008</pub-id>
          <pub-id pub-id-type="pmid">17229461</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bast</surname>
              <given-names>RC</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Klug</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Schaetzl</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lavin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Niloff</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Greber</surname>
              <given-names>TF</given-names>
            </name>
            <name>
              <surname>Zurawski</surname>
              <given-names>VR</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Knapp</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen</article-title>
          <source>Am J Obstet Gynecol</source>
          <year>1984</year>
          <volume>149</volume>
          <issue>5</issue>
          <fpage>553</fpage>
          <lpage>559</lpage>
          <pub-id pub-id-type="doi">10.1016/0002-9378(84)90035-8</pub-id>
          <pub-id pub-id-type="pmid">6204531</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
